稳定期慢性阻塞性肺疾病治疗用中成药的潜在用药风险分析 点击下载
| 论文标题： | 稳定期慢性阻塞性肺疾病治疗用中成药的潜在用药风险分析 |
| 英文标题： | |
| 中文摘要： | 目的：探讨稳定期慢性阻塞性肺疾病（COPD）治疗用中成药的潜在用药风险，为保障临床用药安全提供参考。方法：计算机检索中国期刊全文数据库、中国生物医学文献数据库、万方数据库和维普网等中文数据库，以“稳定期“”慢性阻塞性肺疾病”“COPD“”中成药”等为检索词，检索稳定期COPD治疗用中成药相关的文献，检索时限为各库建库起至2019年9月。收集稳定期COPD治疗用中成药种类及成分，从中药配伍禁忌、中药与化学药的相互作用以及中成药对稳定期COPD常见合并其他慢病的影响等方面，对此类中成药的潜在用药风险进行分析。结果：共纳入11篇文献，涉及29种用于治疗稳定期COPD的中成药，其中2种含附子的中成药与11种含“半蒌贝蔹及”的中成药之间存在“十八反“”十九畏”的配伍禁忌；4种中成药因含有麻黄成分，需避免与β2受体激动药和茶碱类化学药联用；且口服类抗菌药物与14种含甘草成分的中成药同时服用会降低疗效。此外，合并患有高血压、高血脂或糖尿病的稳定期COPD患者，需慎用含有甘草、附子、麻黄、枳壳、山茱萸、川贝母、人参与三七等成分的此类中成药。结论：稳定期COPD治疗用中成药存在多因素的潜在用药风险（如联用、配伍风险），建议用药前全面评估患者的既往病史和其他用药情况，从而科学地指导临床合理用药。 |
| 英文摘要： | OBJECTIVE：To study the potential ris k of Chinese patent medicine for the treatment of stable chronic obstructive pulmonary disease （COPD），and to provide reference for the safety of clinical drug use. METHODS ：Retrieved from Chinese journal full-text database ，CBM，Wanfang database and VIP ，using“stable”“Chronic obstructive pulmonary disease ”“COPD” “Chinese patent medicine ”as retrieval words ，relative literatures about Chinese patent medicine in the treatment of stable COPD were retrieved ，and retrieval time limitation was from their establishment to Sept. 2019. The type and components of Chinese patent medicine were collected. The potential risk of Chinese patent medicine was analyzed in terms of the contraindications of traditional Chinese medicines ，the interaction between traditional Chinese medicines and chemical medicines ，and its effects on stable COPD with other common chronic diseases. RESULTS ：Eleven related studies covering 29 kinds of Chinese patent medicines for the treatment of stable COPD were included in this study. There were several incompatibility between two Chinese patent medicines containing Aconitum carmichaelii and eleven Chinese patent medicines containing “Pinellia ternata ，Trichosanthes kirilowii ， Bolbostemma paniculatum ，Ampelopsis japonica ，Bletilla striata ”as an ancient rule of traditional Chinese medicine incompatibility “Eighteen antagonisms ”and“Nineteen mutual ”inhibitors. Meanwhile ，it should be avoided that four Chinese patent medicines containing ephedra combined with β2 receptor agonists or theophylline. Moreover ，oral antibiotics and 14 kinds of Chinese patent medicine containing licorice would reduce the curative effect. In addition ，patients with stable COPD who also had hypertension ， hyperlipidemia or diabetes should be careful to use Chinese patent medicines containing ingredients such as Glycyrrhiza uralensis ， A. carmichaelii ，Ephedra sinica ，Citrus aurantium ，Cornus officinalis ，Fritillaria cirrhosa ，Panax ginseng （Panax notoginseng ）. CONCLUSIONS：There are many potential risks （such as combined use ，compatibility）in the use of Chinese patent medicines for stable COPD. It is suggested to comprehensively evaluate the patient ’s previous medical history and medication before using Chinese patent medicines ，so as to provide scientific guide for clinical rational medication. |
| 期刊： | 2020年第31卷第07期 |
| 作者： | 郑春霞，郑晓英，孔令希，邱峰，单雪峰 |
| 英文作者： | ZHENG Chunxia ，ZHENG Xiaoying ，KONG Lingxi ，QIU Feng，SHAN Xuefeng |
| 关键字： | 稳定期慢性阻塞性肺疾病；中成药；药物联用；配伍禁忌；用药风险 |
| KEYWORDS： | Stable chronic obstructive pulmonary disease ；Chinese patent medicine ；Drug combination ；Incompatibility； |
| 总下载数： | 81次 |
| 本日下载数： | 2次 |
| 本月下载数： | 81次 |
| 文件大小： | 619.60Kb |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！